Pawel Kalinski, M.D./Ph.D.
Department of Surgery
Univeristy of Pittsburgh
HCC Suite 1.46
5117 Centre Avenue
Pittsburgh, PA 15213
The focus of research conducted in Dr. Kalinski’s laboratory is the development of cancer treatments that simultaneously target the induction and effector phase of tumor-specific immune responses and use the paradigms of effective anti-viral immunity. Exposing maturing dendritic cells (DCs) simultaneously to cancer antigens and mediators of anti-viral responses, Dr. Kalinski’s group developed type-1-polarized DC1s with selectively enhanced Th1-, CTL- and NK cell-activating properties and tumor-selective modulation of chemokine production. Combined application of DC1s with interferons, Toll-like receptor ligands and prostaglandin inhibitors, aims to recreate the conditions of viral infection within tumor tissues to enhance the homing of vaccination-induced T cells into tumors and their local anti-tumor functions.
Kalinski P. (2012). Regulation of immune responses by prostaglandin E2. J Immunol. 188: 21-28.
Kalinski P, Edington H, Zeh HJ, Okada H, Butterfield LH, Kirkwood JM, Bartlett DL. 92011). Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunol Res. 50: 235-247.
Wong JL, Mailliard RB, Moschos SJ, Edington H, Lotze MT, Kirkwood JM, Kalinski P. (2011). Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells. J Immunother. 34: 270-278.
Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P. (2004). alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64: 5934-5937.